Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

The role of cytochrome P450 BM3 phenylalanine-87 and threonine-268 in binding organic hydroperoxides.

Roberts AG, Katayama J, Kaspera R, Ledwitch KV, Le Trong I, Stenkamp RE, Thompson JA, Totah RA.

Biochim Biophys Acta. 2016 Apr;1860(4):669-77. doi: 10.1016/j.bbagen.2015.12.014. Epub 2015 Dec 23.

PMID:
26723172
2.

Discovery of potent KIFC1 inhibitors using a method of integrated high-throughput synthesis and screening.

Yang B, Lamb ML, Zhang T, Hennessy EJ, Grewal G, Sha L, Zambrowski M, Block MH, Dowling JE, Su N, Wu J, Deegan T, Mikule K, Wang W, Kaspera R, Chuaqui C, Chen H.

J Med Chem. 2014 Dec 11;57(23):9958-70. doi: 10.1021/jm501179r. Epub 2014 Dec 2.

PMID:
25458601
3.

Investigating the contribution of CYP2J2 to ritonavir metabolism in vitro and in vivo.

Kaspera R, Kirby BJ, Sahele T, Collier AC, Kharasch ED, Unadkat JD, Totah RA.

Biochem Pharmacol. 2014 Sep 1;91(1):109-18. doi: 10.1016/j.bcp.2014.06.020. Epub 2014 Jun 25.

4.

Activity, inhibition, and induction of cytochrome P450 2J2 in adult human primary cardiomyocytes.

Evangelista EA, Kaspera R, Mokadam NA, Jones JP 3rd, Totah RA.

Drug Metab Dispos. 2013 Dec;41(12):2087-94. doi: 10.1124/dmd.113.053389. Epub 2013 Sep 10.

5.

Extra-hepatic isozymes from the CYP1 and CYP2 families as potential chemotherapeutic targets.

Raccor BS, Kaspera R.

Curr Top Med Chem. 2013;13(12):1441-53. Review.

PMID:
23688134
6.

OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis.

Tamraz B, Fukushima H, Wolfe AR, Kaspera R, Totah RA, Floyd JS, Ma B, Chu C, Marciante KD, Heckbert SR, Psaty BM, Kroetz DL, Kwok PY.

Pharmacogenet Genomics. 2013 Jul;23(7):355-64. doi: 10.1097/FPC.0b013e3283620c3b.

7.

A screening study of drug-drug interactions in cerivastatin users: an adverse effect of clopidogrel.

Floyd JS, Kaspera R, Marciante KD, Weiss NS, Heckbert SR, Lumley T, Wiggins KL, Tamraz B, Kwok PY, Totah RA, Psaty BM.

Clin Pharmacol Ther. 2012 May;91(5):896-904. doi: 10.1038/clpt.2011.295. Epub 2012 Mar 14.

8.

Protein tyrosine nitration of mitochondrial carbamoyl phosphate synthetase 1 and its functional consequences.

Takakusa H, Mohar I, Kavanagh TJ, Kelly EJ, Kaspera R, Nelson SD.

Biochem Biophys Res Commun. 2012 Mar 30;420(1):54-60. doi: 10.1016/j.bbrc.2012.02.114. Epub 2012 Feb 28.

9.

Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.

Lee CA, Jones JP 3rd, Katayama J, Kaspera R, Jiang Y, Freiwald S, Smith E, Walker GS, Totah RA.

Drug Metab Dispos. 2012 May;40(5):943-51. doi: 10.1124/dmd.111.043505. Epub 2012 Feb 10.

10.

Cytochrome P450BM-3 reduces aldehydes to alcohols through a direct hydride transfer.

Kaspera R, Sahele T, Lakatos K, Totah RA.

Biochem Biophys Res Commun. 2012 Feb 17;418(3):464-8. doi: 10.1016/j.bbrc.2012.01.040. Epub 2012 Jan 18.

PMID:
22281497
11.

Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5.

Kaspera R, Naraharisetti SB, Evangelista EA, Marciante KD, Psaty BM, Totah RA.

Biochem Pharmacol. 2011 Sep 15;82(6):681-91. doi: 10.1016/j.bcp.2011.06.027. Epub 2011 Jun 24.

12.

Cerivastatin, genetic variants, and the risk of rhabdomyolysis.

Marciante KD, Durda JP, Heckbert SR, Lumley T, Rice K, McKnight B, Totah RA, Tamraz B, Kroetz DL, Fukushima H, Kaspera R, Bis JC, Glazer NL, Li G, Austin TR, Taylor KD, Rotter JI, Jaquish CE, Kwok PY, Tracy RP, Psaty BM.

Pharmacogenet Genomics. 2011 May;21(5):280-8. doi: 10.1097/FPC.0b013e328343dd7d.

13.

Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis.

Kaspera R, Naraharisetti SB, Tamraz B, Sahele T, Cheesman MJ, Kwok PY, Marciante K, Heckbert SR, Psaty BM, Totah RA.

Pharmacogenet Genomics. 2010 Oct;20(10):619-29. doi: 10.1097/FPC.0b013e32833ecace.

14.

Synthesis and In Vitro Evaluation of Taxol oxetane ring D precursors.

Kaspera R, Cape JL, Faraldos JA, Ketchum RE, Croteau RB.

Tetrahedron Lett. 2010 Apr 14;51(15):2017-2019.

15.

Epoxyeicosatrienoic acids: formation, metabolism and potential role in tissue physiology and pathophysiology.

Kaspera R, Totah RA.

Expert Opin Drug Metab Toxicol. 2009 Jul;5(7):757-71. doi: 10.1517/17425250902932923. Review.

PMID:
19505190
16.

Cytochrome P450 oxygenases of Taxol biosynthesis.

Kaspera R, Croteau R.

Phytochem Rev. 2006 Jun;5(2-3):433-444.

17.

Taxol biosynthesis and molecular genetics.

Croteau R, Ketchum RE, Long RM, Kaspera R, Wildung MR.

Phytochem Rev. 2006 Feb;5(1):75-97.

18.

Regio- and stereoselective fungal oxyfunctionalisation of limonenes.

Kaspera R, Krings U, Pescheck M, Sell D, Schrader J, Berger RG.

Z Naturforsch C J Biosci. 2005 May-Jun;60(5-6):459-66.

PMID:
16042348
19.

Bioconversion of (+)-valencene in submerged cultures of the ascomycete Chaetomium globosum.

Kaspera R, Krings U, Nanzad T, Berger RG.

Appl Microbiol Biotechnol. 2005 Jun;67(4):477-83. Epub 2004 Dec 16.

PMID:
15602686

Supplemental Content

Loading ...
Support Center